These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose. Kalheim LF; Fladby T; Coello C; Bjørnerud A; Selnes P J Alzheimers Dis; 2018; 62(4):1595-1607. PubMed ID: 29504529 [TBL] [Abstract][Full Text] [Related]
5. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. Adamczuk K; Schaeverbeke J; Vanderstichele HM; Lilja J; Nelissen N; Van Laere K; Dupont P; Hilven K; Poesen K; Vandenberghe R Alzheimers Res Ther; 2015 Dec; 7(1):75. PubMed ID: 26677842 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
8. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286 [TBL] [Abstract][Full Text] [Related]
10. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]
11. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549 [TBL] [Abstract][Full Text] [Related]
12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012 [TBL] [Abstract][Full Text] [Related]
14. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669 [TBL] [Abstract][Full Text] [Related]
15. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
16. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653 [TBL] [Abstract][Full Text] [Related]
17. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment. He B; Wang L; Xu B; Zhang Y; Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589 [TBL] [Abstract][Full Text] [Related]
19. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study. Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253 [TBL] [Abstract][Full Text] [Related]
20. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status. Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]